Advertisement

An Evaluation of Two Different Schedules of Synthetic Thymosin α1 Administration in Patients with Lung Cancer

Preliminary Results
  • Richard S. Schulof
  • Margaret Lloyd
  • John Cox
  • Susan Palaszynski
  • John E. McClure
  • Genevieve S. Incefy
  • Allan L. Goldstein
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)

Abstract

Thymosin α1 (molecular weight 3108) is one of the many active polypeptides isolated from thymosin fraction 5 (TF5) (Low and Goldstein, 1979; Goldstein et al., 1982). α1 was initially purified from extracts of calf thymus glands. Biologically active α1 has now been successfully synthesized by classical solution (Birr and Stollenwerk, 1979; Wang et al., 1978), solid-phase (Wang et al., 1980; Folkers, et al., 1980) and recombinant DNA procedures (Wetzel et al., 1980).

Keywords

Serial Monitoring Surgical Reduction Thymic Hormone Thymic Factor Immunosuppressed Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bentwich, Z., Douglas, S. D., Siegal, F. P., and Kunkel, H. G., 1973, Human lymphocyte-sheep erythrocyte rosette formation: some characteristics of the interaction, Clin. Immunol. Immunopathol. 1:511–522.PubMedCrossRefGoogle Scholar
  2. Birr, C, and Stollenwerk, U., 1979, Synthesis of thymosin 03b11, a polypeptide of the thymus, Angew.Chem. 91:422.CrossRefGoogle Scholar
  3. Cohen, M. H., Chretien, P. A., Ihle, D. C., Fossieck, B. E., Makuch, R., Bunn, P. A., Johnston, A. V., Shackney, S. E., Mathews, M. J., Lipson, S. D., Kenady, D. E., and Minna, J. D., 1979, Thymosin fraction V and intensive combination chemotherapy prolonging the survival of patients with small-cell lung cancer, J. Am. Med. Assoc. 241:1813–1815.CrossRefGoogle Scholar
  4. Dardenne, M., and Bach, J.-F., 1973, Studies on thymus products: Mofidifcation of rosette-forming cells by thymic extracts. I. Determination of the target RFC subpopulation, Immunology 25:343–352.PubMedGoogle Scholar
  5. Dillman, R. O., Beauregard, J. C., Medelsohn, J., Green, M. R., Howell, S. B., and Royston, I., 1982, Phase I trial of thymosin fraction 5 and thymosin α1, J. Biol. Resp. Mod. 1:35–42.Google Scholar
  6. Dillman, R. O., Beauregard, J. C., Zavanelli, M. I., Halliburton, B. L., Wormsley, S., and Royston, I., 1983, In vivo immune restoration in advanced cancer patients after administration of thymosin fraction 5 or thymosin α1, J. Biol. Resp. Mod. 2:139–149.Google Scholar
  7. Folkers, K., Lehan, J., Sakura, N., Rampold, G., Lundanes, E., Dahmen, J., Lebek, M., Ohta, J., and Bowers, C. Y., 1980, Current advances on biologically active synthetic peptides, in: Polypeptide Hormones (R. F. Beers and E. G. Bassett, eds.), p. 149, Raven Press, New York.Google Scholar
  8. Goldstein, A. L., Low, T. L. K., Thurman, G. B., Zatz, M. M., Hall, N., Chen, J., Hu, S. K., Naylor, P. B., and McClure, J. E., 1980, Current status of thymosin and other hormones of the thymus gland, Recent Prog. Horm. Res. 37:369–416.Google Scholar
  9. Goldstein, A. L., Low, T. L. K., Thurman, G. B., Zatz, M. M., Hall, N. R., McClure, J. E., Hu, S. K., and Schulof, R. S., 1982, Thymosins and other hormone-like factors of the thymus gland, in: Immunological Approaches to Cancer Therapeutics(E. Mihich, ed.), pp. 137–190, John Wiley and Sons, New York.Google Scholar
  10. Iwata, T., Incefy, G. S., Cunningham-Rundles, G., Smithwick, E., Geller, N., O’Reilly, R., and Good, R., 1981, Circulating thymic hormone activity in patients with primary and secondary immunodeficiency diseases, Am. J. Med. 71:385–394.PubMedCrossRefGoogle Scholar
  11. Kaplan, E. L., and Meier, P., 1958, Non-parametric estimation from incomplete observations, J. Am.Stat. Assoc. 53:457–481.CrossRefGoogle Scholar
  12. Low, T. L. K., and Goldstein, A. L., 1979, The chemistry and biology of thymosin. II. Amino acid sequence analysis of thymosin α1 and polypeptide β1, J. Biol. Chem. 254:987–995.PubMedGoogle Scholar
  13. McClure, J. E., Lameris, N., Wara, D. W., and Goldstein, A. L., 1982, Immunochemical studies on thymosin: Radioimmunoassay of thymosin α1, J. Immunol. 128:368–375.PubMedGoogle Scholar
  14. McGillis, J., Hall, N., and Goldstein, A. L., 1983, Circadian rhythm of thymosin α1 in normal and thymectomized mice, J. Immunol. 131:148–151.PubMedGoogle Scholar
  15. Reinherz, E. L., and Schlossman, S. F., 1980, The differentiation and function of human T lymphocytes, Cell 19:821–827.PubMedCrossRefGoogle Scholar
  16. Roswit, B., Patno, M. E., Rapp, R., Veinbergs, A., Feder, B., Stuhlbarg, J., and Reid, C., 1968, The survival of patients with inoperable lung cancer: A large-scale randomized study of radiation therapy versus placebo, Radiology 90:688.PubMedGoogle Scholar
  17. Schulof, R. S., Lacher, M. J., and Gupta, S., 1981, Abnormal phytohemagglutinin-induced T-cell proliferative responses in Hodgkin’s disease, Blood 57:607–613.PubMedGoogle Scholar
  18. Schulof, R. S., Lloyd, M., Cox, J., Palaszynski, S., Mai, D., McClure, J., and Goldstein, A. L., 1982, The immunopharmacology and pharmacokinetics of thymosin 03b11 administration in man: A prototypic thymic hormone efficacy trial in patients with lung cancer, in: Current Concepts inHuman Immunology and Cancer Immunomodulation (Serrou, C. Rosenfeld, J. C. Daniels, and J. P. Saunders, eds.), p. 545, Elsevier, Amsterdam.Google Scholar
  19. Snedecor, G. W., and Cochran, W. G., 1980, Statistical Methods, 7th ed., pp. 83–102, 175–191, Iowa State University, Ames.Google Scholar
  20. Wang, S. S., Kulesha, I. D., Winter, D. P., 1978, Synthesis of thymosin α1, Journal Amer. Chem.Soc. 101:253–250.CrossRefGoogle Scholar
  21. Wang, S. S., Mokofska, R., Bach, A. E., and Merrifield, R. B., 1980 Solid phase synthesis of thymosin α1, Int. J. Pept. Protein Res. 15:1–5.PubMedCrossRefGoogle Scholar
  22. Wara, W. M., Neely, M. H., Ammann, A. J., and Wara, D. W., 1981, Biologic modification of immunologic parameters in head and neck cancer patients treated with thymosin fraction V, in: Lymphokines and Thymic Hormones: Their Potential Utilization in Cancer Therapeutics (A. L. Goldstein and M. A. Chirigos, eds.), pp. 257–262, Raven Press, New York.Google Scholar
  23. West, W. W., Sienknecht, C. W., Townes, A. S., and Herberman, R. B., 1976, Performance of a rosette assay between lymphocytes and sheep erythrocytes at elevated temperatures to study patients with cancer and other diseases, Clin. Immunol. Immunopathol. 5:60–66.PubMedCrossRefGoogle Scholar
  24. Wetzel, R., Heyneker, H. L., Goeddel, D. V., Thurani, P., Shapiro, J., Crea, R., Low, T. L. K., McClure, J. E., and Goldstein, A. L., 1980, Production of biologically active Nα-desacetylthymosin α1 in Escherichia coli through expression of a chemically synthesized gene, Biochemistry 19:6096–6104.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Richard S. Schulof
    • 1
  • Margaret Lloyd
    • 2
  • John Cox
    • 2
  • Susan Palaszynski
    • 2
  • John E. McClure
    • 3
  • Genevieve S. Incefy
    • 4
  • Allan L. Goldstein
    • 3
  1. 1.Departments of Medicine and BiochemistryThe George Washington University School of Medicine and Health SciencesUSA
  2. 2.Department of MedicineThe George Washington University School of Medicine and Health SciencesUSA
  3. 3.Department of BiochemistryThe George Washington University School of Medicine and Health SciencesUSA
  4. 4.The Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations